Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Capital Expenditures: 2015-2024

Historic Capital Expenditures for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Dec 2024 value amounting to $5.9 million.

  • Rocket Pharmaceuticals' Capital Expenditures fell 103.40% to -$54,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $669,000, marking a year-over-year decrease of 93.44%. This contributed to the annual value of $5.9 million for FY2024, which is 64.33% down from last year.
  • As of FY2024, Rocket Pharmaceuticals' Capital Expenditures stood at $5.9 million, which was down 64.33% from $16.4 million recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' Capital Expenditures registered a high of $20.6 million during FY2020, and its lowest value of $5.9 million during FY2024.
  • Moreover, its 3-year median value for Capital Expenditures was $8.4 million (2022), whereas its average is $10.2 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Capital Expenditures skyrocketed by 96.65% in 2023, and later crashed by 64.33% in 2024.
  • Over the past 5 years, Rocket Pharmaceuticals' Capital Expenditures (Yearly) stood at $20.6 million in 2020, then plummeted by 63.02% to $7.6 million in 2021, then increased by 9.69% to $8.4 million in 2022, then soared by 96.65% to $16.4 million in 2023, then plummeted by 64.33% to $5.9 million in 2024.